How Your Opioid Peptides Control Pain

Beta-Endorphin

700x more potent

Dynorphin-(1-13) was found to be 700 times more potent than leu-enkephalin in the guinea pig ileum assay, making it one of the strongest endogenous opioid peptides ever characterized.

Goldstein et al., Proceedings of the National Academy of Sciences, 1979

Goldstein et al., Proceedings of the National Academy of Sciences, 1979

View as image

Your body produces its own opioids. Three families of endogenous opioid peptides, endorphins, enkephalins, and dynorphins, modulate pain perception at every level of the nervous system, from peripheral nerve endings to the spinal cord to the brain. These peptides bind the same receptors that morphine and fentanyl target, but they are released in precise amounts at specific locations to control pain without the systemic flooding that makes pharmaceutical opioids dangerous. For broader context on these three peptide families, see the pillar article on beta-endorphin and the runner's high.

Understanding how endogenous opioid peptides modulate pain is not just academic. It explains why some people tolerate pain better than others, why stress can temporarily eliminate pain, why placebos work, and why the opioid addiction crisis involves hijacking a system that evolved for survival.

The Three Peptide Families and Their Receptors

Each opioid peptide family is derived from a distinct precursor protein processed by specific enzymes in specific tissues.

Endorphins are cleaved from pro-opiomelanocortin (POMC), primarily in the pituitary gland and the arcuate nucleus of the hypothalamus. Beta-endorphin, the most studied member, is a 31-amino-acid peptide that preferentially binds mu opioid receptors (MOR). Schoffelmeer and colleagues demonstrated in 1991 that beta-endorphin is a "highly selective endogenous opioid agonist for presynaptic mu opioid receptors," with binding affinity measurements showing clear MOR preference under physiological conditions.^[1]

Enkephalins are derived from proenkephalin (PENK) and exist as two pentapeptides: met-enkephalin and leu-enkephalin. They are the most widely distributed opioid peptides in the central nervous system, found in interneurons throughout the spinal cord dorsal horn, the periaqueductal gray (PAG), the amygdala, and the rostral ventromedial medulla (RVM). Enkephalins preferentially bind delta opioid receptors (DOR) but also activate MOR.

Dynorphins are processed from prodynorphin (PDYN) and preferentially bind kappa opioid receptors (KOR). Goldstein and colleagues characterized dynorphin-(1-13) in 1979 as "an extraordinarily potent opioid peptide," measuring 700-fold greater potency than leu-enkephalin in the guinea pig ileum assay.^[2] All effects were completely blocked by naloxone, confirming opioid receptor-mediated action. Dynorphins play a more complex role than the other families: they produce analgesia in some circuits but can promote pain (pronociception) and dysphoria through kappa receptor activation in others. The cross-cluster article on dynorphin and the kappa receptor examines this dual nature.

The sibling article on endorphins, enkephalins, and dynorphins covers the biosynthesis and distribution of each family in detail.

The Descending Pain Modulation Circuit

The most powerful pain control system in the body is the descending modulatory circuit, a series of interconnected brain regions that can amplify or suppress pain signals traveling up from the spinal cord.

The circuit flows from the amygdala and hypothalamus through the periaqueductal gray (PAG) to the rostral ventromedial medulla (RVM) and then down to the spinal cord dorsal horn. At each relay point, endogenous opioid peptides act as critical modulators.

In the PAG, enkephalins released from terminals originating in the amygdala activate mu opioid receptors on GABAergic interneurons. Under resting conditions, these interneurons tonically inhibit PAG output neurons. When enkephalins bind MOR on the GABAergic cells, the inhibition is removed (a process called disinhibition), allowing PAG output neurons to activate the RVM. The RVM then sends descending projections to the spinal cord that suppress incoming pain signals.

This disinhibition mechanism is elegant: opioid peptides do not directly excite pain-suppressing neurons. Instead, they silence the inhibitory neurons that normally keep pain suppression turned off. The system defaults to "pain allowed" and must be actively switched to "pain suppressed" by opioid peptide release. This default explains why blocking opioid receptors with naloxone increases pain sensitivity: you are removing the ongoing suppression that endogenous opioids provide.

Spinal Cord: The Gate

The spinal cord dorsal horn is where ascending pain signals from peripheral nerves can be amplified or gated before reaching the brain. Enkephalin-containing interneurons in the superficial dorsal horn (laminae I and II) provide local opioid modulation at this critical relay point.

Tseng and colleagues demonstrated in 1989 that intrathecal met-enkephalin antibody blocked the analgesic effects of intracerebroventricularly administered beta-endorphin on the tail-flick test (a spinal reflex) but not on the hot-plate test (a supraspinal response).^[3] This proved that beta-endorphin's spinal analgesia depends partly on triggering local enkephalin release in the spinal cord. The brain's beta-endorphin activates a cascade that releases spinal enkephalins, which then directly inhibit pain transmission at the dorsal horn.

Gutstein and colleagues added important anatomical context in 1992 by demonstrating that the spinal cord produces its own beta-endorphin locally, not just receiving it from descending projections.^[4] POMC processing products were found in rat spinal cord cells, suggesting that both local production and descending release contribute to spinal opioid analgesia.

At the cellular level, opioid peptides modulate pain transmission in the dorsal horn through two mechanisms: presynaptically, they inhibit calcium influx into primary afferent terminals, reducing the release of pain neurotransmitters (substance P, glutamate); postsynaptically, they open potassium channels that hyperpolarize dorsal horn projection neurons, making them less responsive to incoming signals. Both mechanisms work simultaneously to reduce pain signal transmission from the spinal cord to the brain. For cross-cluster context on the pain-amplifying peptide that opioids oppose, see substance P and pain.

Peripheral Opioid Analgesia

Endogenous opioid peptides do not act exclusively in the brain and spinal cord. Opioid receptors are expressed on peripheral sensory nerve terminals, and immune cells at injury sites release opioid peptides that provide local pain control.

Rittner and colleagues showed in 2009 that neutrophil-derived opioid peptides produce antinociception in peripheral tissues even without active inflammation.^[5] The mechanism requires hypertonic conditions that expose opioid receptors on sensory nerve endings by disrupting the perineurial barrier. This finding expanded the understanding of peripheral opioid analgesia beyond the inflammatory context, showing that immune cells carry a portable pharmacy of opioid peptides that can be deployed wherever neutrophils accumulate.

Khalefa and colleagues compared the peripheral antinociceptive efficacy of endogenous peptide agonists (met-enkephalin, beta-endorphin) with synthetic opioids (morphine, fentanyl) in a localized inflammatory pain model in 2013.^[6] The study provided direct efficacy comparisons between endogenous and exogenous opioids at peripheral receptors, establishing that endogenous peptides produce meaningful analgesia at the injury site without the systemic effects of circulating opioid drugs.

Stress-Induced Analgesia: The Emergency Override

One of the most dramatic demonstrations of endogenous opioid function is stress-induced analgesia (SIA). During extreme physical stress, injury, or threat, the body releases a surge of beta-endorphin and enkephalins that can suppress pain entirely. Soldiers wounded in combat, athletes injured during competition, and accident victims frequently report feeling no pain at the time of injury, with pain appearing only hours later when the stress response subsides.

The mechanism involves massive activation of the descending modulatory circuit. The hypothalamus and amygdala, both stress-responsive regions, send strong opioidergic projections to the PAG. Under extreme stress, these projections release enough beta-endorphin and enkephalin to maximally activate the descending pathway, effectively silencing pain transmission from the spinal cord. Fontana and colleagues showed in 1997 that opioid peptides modulate not just pain but the entire stress response, including cardiovascular and endocrine changes during mental stress.^[9]

This emergency override evolved for survival: an animal that cannot flee because of pain will not survive the predator that caused the injury. But the system has limits. It functions for minutes to hours, not days. When the stress response ends, the pain returns, often intensified because the injury may have worsened during the period of analgesia.

Maestroni and colleagues demonstrated in 1989 that beta-endorphin and dynorphin also modulate immune function during stress, mimicking the effects of melatonin on antibody production and anti-viral resistance.^[10] This connects pain modulation to immune regulation: the same peptides that suppress pain during stress simultaneously adjust immune function, coordinating the body's entire defensive response.

Frequency-Dependent Release: The Acupuncture Evidence

One of the most striking demonstrations of differential opioid peptide release came from electroacupuncture research. Han reviewed the evidence in 2004, documenting that different electrical stimulation frequencies release different endogenous opioid peptides from different brain regions.^[7]

Low-frequency stimulation (2 Hz) preferentially releases enkephalins and beta-endorphin, producing analgesia through mu and delta receptors. High-frequency stimulation (100 Hz) preferentially releases dynorphin, producing analgesia through kappa receptors. Mixed-frequency stimulation (alternating 2/100 Hz) releases all three peptide types and produces the strongest analgesic effect.

This frequency dependence is not unique to acupuncture. Transcutaneous electrical nerve stimulation (TENS), exercise, and other forms of physiological stress can differentially activate opioid peptide release depending on intensity, duration, and pattern. The sibling article on mu, kappa, and delta receptors covers how each receptor type contributes to the analgesic response.

Chronic Pain: When the System Breaks Down

The endogenous opioid system is designed for acute pain modulation, not continuous suppression of chronic pain. When pain becomes persistent, the system undergoes maladaptive changes.

Przewlocki and colleagues reviewed opioids in chronic pain in 2001, documenting multiple failure modes.^[8] Chronic pain states produce receptor downregulation (fewer opioid receptors on the cell surface, reducing sensitivity to endogenous peptides), altered peptide processing (changes in how precursor proteins are cleaved, potentially producing different active fragments), and shifted circuit dynamics (the descending modulatory system can switch from pain suppression to pain facilitation).

The shift from suppression to facilitation is particularly important. In some chronic pain conditions, the same RVM neurons that normally suppress spinal pain transmission begin to enhance it. Dynorphin levels increase in the spinal cord during chronic pain, and kappa receptor activation by elevated dynorphin contributes to pain maintenance rather than relief. This paradoxical role of dynorphin distinguishes chronic pain neurobiology from acute pain processing: the same peptide that helps control acute pain can perpetuate chronic pain.

This maladaptive remodeling also explains opioid tolerance: when exogenous opioids chronically stimulate the system, the same receptor downregulation and circuit changes occur, progressively reducing both the efficacy of the drug and the effectiveness of the body's own pain control. For more on how opioid systems intersect with addiction, see the cross-cluster article on endogenous opioid peptides and addiction.

The Bottom Line

Endogenous opioid peptides modulate pain through a layered system: beta-endorphin activates mu receptors in the descending pain circuit, enkephalins gate pain signals at the spinal cord, and dynorphins act through kappa receptors with complex pro- and anti-nociceptive effects. These peptides also provide peripheral analgesia through immune cell release at injury sites. The system is optimized for acute pain control and can malfunction in chronic pain states, with receptor downregulation, altered peptide processing, and paradoxical pain facilitation.

Frequently Asked Questions

How do endogenous opioid peptides reduce pain?

Endogenous opioid peptides reduce pain by activating opioid receptors at three levels: in the brain (descending pain modulation circuit), the spinal cord (gating pain signals), and peripheral tissues (immune cells releasing opioids at injury sites). At the cellular level, they inhibit calcium influx to reduce pain neurotransmitter release and open potassium channels to hyperpolarize pain-transmitting neurons.

What is the difference between endorphins enkephalins and dynorphins?

Each comes from a different precursor protein and prefers a different receptor. Beta-endorphin (from POMC) preferentially binds mu receptors and is released from the pituitary during stress and exercise. Enkephalins (from proenkephalin) prefer delta receptors and are the most widely distributed opioid peptides in the spinal cord. Dynorphins (from prodynorphin) prefer kappa receptors and have complex dual effects on pain.

What is the descending pain modulation circuit?

The descending pain circuit runs from the amygdala and hypothalamus through the periaqueductal gray (PAG) to the rostral ventromedial medulla (RVM) and down to the spinal cord. Enkephalins in the PAG silence inhibitory interneurons through disinhibition, allowing PAG output neurons to activate pain-suppressing pathways that reduce pain signal transmission from the spinal cord to the brain.

Why does exercise reduce pain through endorphins?

Exercise triggers beta-endorphin release from the pituitary gland and brain regions involved in pain modulation. These endorphins bind mu opioid receptors in the descending pain circuit, activating the same pathways that morphine targets. Han (2004) showed different physical stimulation patterns release different opioid peptides, with the combination producing the strongest analgesic effect.

Why does the opioid pain system fail in chronic pain?

Chronic pain causes receptor downregulation (fewer opioid receptors), altered peptide processing (different active fragments), and paradoxical circuit switching where the descending system facilitates pain instead of suppressing it. Przewlocki et al. (2001) documented that dynorphin levels increase in the spinal cord during chronic pain, and kappa receptor activation by this elevated dynorphin perpetuates rather than relieves the pain.

Do immune cells release opioid peptides for pain relief?

Yes. Rittner et al. (2009) showed that neutrophils release opioid peptides that bind opioid receptors on peripheral sensory nerve terminals, producing local pain relief at injury sites. This peripheral opioid analgesia works even without active inflammation when hypertonic conditions expose the nerve receptors. Immune cells essentially carry a portable opioid pharmacy to wherever they accumulate.